Navigation Links
Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
Date:8/10/2011

THE WOODLANDS, Texas, Aug. 10, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.  The issue also included an expert editorial discussing the study, its implications and the potential utility of this mechanism of action in gastrointestinal disease.

Results of the Phase 2 study showed that the tryptophan hydroxylase inhibitor, LX1031, was well tolerated and provided clinical benefit to patients with non-constipating IBS, showing improvements in a global assessment of adequate relief from IBS pain and discomfort and in stool consistency.  Notably, symptom relief correlated with reduced levels of 5-HIAA, a biomarker of serotonin production.

Lexicon recently completed a Phase 1 study of LX1033, a follow-on compound that is significantly more potent than LX1031.  In the study, LX1033 produced reductions in the 5-HIAA biomarker in healthy volunteers comparable to those seen with LX1031, but with lower and less frequent dosing.  Lexicon intends to advance LX1033 into a Phase 2 clinical trial as its lead drug candidate in IBS.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were d
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
2. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
3. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
4. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
5. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
6. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
7. Lexicon to Provide First Quarter 2011 Financial Results
8. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
9. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
11. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... 15, 2011 XTIO2 INC . ... the XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM ... XTI™  Nano-Facemask . It is the world,s most ... transmitted via air and contact surfaces. The unique nanocoating ...
... Motion Therapeutics, Inc. http://www.motiontherapeutics.com , the leading ... disorders, today announced that researchers at Samuel Merritt University ... Grant to study the effects of wearing a strategically ... with MS. This grant comes after ...
Cached Medicine Technology:OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 2OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 3The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant 2
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
(Date:4/22/2014)... have found a way to block abnormal cholesterol production, ... the main cause of heart attacks and strokes and ... develops when fat builds inside blood vessels over time ... their ability to feed oxygen-rich blood to the heart ... experiments, described April 7 in the journal Circulation ...
(Date:4/22/2014)... tool developed at the University of Utah (U of ... in three separate cases, U of U researchers and ... The American Journal of Human Genetics . The software, ... illnesses and unknown gene mutations by analyzing the exomes, ... genes are made, in individual patients and small families. ...
(Date:4/22/2014)... This news release is available in German . ... F. Perutz Laboratories of the University of Vienna and the ... Zurich, have now shown how double stranded RNA, such as ... a cell. During the immune response against viral infection, the ... cytoplasm. There it modifies viral RNA to inhibit reproduction of ...
Breaking Medicine News(10 mins):Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... of Buffalo had said that postmenopausal women would have lesser ... periodontal disease at bay. Their research was published in the ... studied 106 postmenopausal women had found that in an average ... one tooth. Their research says that alveolar bone loss is ...
... A nine-year-old boy in a West Bengal town is said to ... his Rip Van Winkle act. // ,Reports Saturday said Arup ... playful boy of eight until 11 months ago when he suddenly ... and recite very well, can now only be half awakened for ...
... Z-Trim fat replacer at a recent show //in New Orleans. ... variety of products without altering the food's original taste. ... Z-Trim fat replacer at a recent show in New Orleans. ... symposia and 14,000 attendees. , ,According to the manufacturers, ...
... small packages. So are the twin electroneedles, which is ... heart attack episodes. The two arrays of micron-sized ... ,Good thing come in small packages. So are ... also said to benefit high-risk cardiac patients by confirming ...
... remains one of the significant health problems to be ... faceted approach. A protein-based diet could help in improving ... shows that consuming a protein hydrolysate and amino acid ... diabetics, and could therefore help individuals control their blood ...
... couples who smoke according to a new study// which has ... than cigarette-smoking women with non-smoking spouses. ,The study recorded ... stroke and ischemic stroke (a stroke caused by a blood ... of women. The relative risk of total stroke was 5.7 ...
Cached Medicine News:Health News:New Insight In Periodontal Disease In Postmenopausal Women 2Health News:New Oat And Soy-Based Fat Replacer Launched 2Health News:Diabetes and heart attack diagnosis now made simple with twin magic 2Health News:Increasing Insulin Response In Type 2 Diabetics With New Protein Mixture 2
REFRESH TEARS® lubricating eye drops does more than just smoothe and relieve dry, irritated eyes. REFRESH TEARS® creates a shield of protection against further irritation with its unique, lon...
... feel dry, scratchy, or irritated, you want ... REFRESH PLUS® lubricant eye drops for mild ... what youre looking for. A couple of ... crave with a special formula that has ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
...
Medicine Products: